[1]Zhang B, Wang M, Sun L, et al. Recent Advances in Targeted Cancer Therapy: Are PDCs the Next Generation of ADCs?. J Med Chem. Published online July 9, 2024.
[2]Nguyen, T. D.; Bordeau, B. M.; Balthasar, J. P. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers 2023, 15 (3), 713.
[3]Lindberg, J.; Nilvebrant, J.; Nygren, P.-A.; Lehmann, F. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. Molecules 2021, 26 (19), 6042.
[4]Fu, C.; Yu, L.; Miao, Y.; Liu, X.; Yu, Z.; Wei, M. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? Acta Pharm. Sin. B 2023, 13 (2), 498−516.
[5]Gong, L.; Zhao, H.; Liu, Y.; Wu, H.; Liu, C.; Chang, S.; Chen, L.; Jin, M.; Wang, Q.; Gao, Z.; et al. Research advances in peptide-drug conjugates. Acta Pharm. Sin. B 2023, 13 (9), 3659−3677.
[6]Heh, E.; Allen, J.; Ramirez, F.; Lovasz, D.; Fernandez, L.; Hogg, T.; Riva, H.; Holland, N.; Chacon, J. Peptide drug conjugates and their role in cancer therapy. Int. J. Mol. Sci. 2023, 24 (1), 829.